Selexis and KBI will provide integrated services to develop Immatics’ bispecific T cell engaging receptor program. Selexis will leverage its SUREtechnology to produce a clonal cell line for Immatics’ candidate IMA402 and KBI Biopharma will utilize its formulation, analytics, and manufacturing capabilities. No financial details have been disclosed. “Selexis and KBI are both JSR Life Sciences companies and are able offer partners integrated services that can accelerate biologic development timelines,” CEO of both companies Dirk Lange told BioProcess Insider. “These…